Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00005887 · ClinicalTrials.gov registry record · Phase 3
Radiation Therapy With or Without RSR13 in Treating Patients With Brain Metastases
A Phase 3 study of Metastatic Cancer, sponsored by Spectrum Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 20
- Study locations
NCT00005887 is a Phase 3 study of Metastatic Cancer that has completed, run by Spectrum Pharmaceuticals. The trial reports 20 study locations across 10 states.
The verdict
NCT00005887, a Phase 3 study of Metastatic Cancer, has completed, sponsored by Spectrum Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 20
- Study locations
Study Summary
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs such as RSR13 may make tumor cells more sensitive to radiation therapy. PURPOSE: Randomized phase III trial to compare the effectiveness of radiation therapy to the brain with or without RSR13 in treating patients who have brain metastases.
Conditions Studied
Interventions
- RADIATION radiation therapy
- DRUG efaproxiral
Study Locations (20)
California
- Alta Bates Comprehensive Cancer Center - Berkeley
- California Cancer Care, Inc. - Greenbrae
- Scripps Green Hospital & Scripps Clinic - La Jolla
- Tower Hematology Oncology Medical Group - Los Angeles
Maryland
- Harbor Hospital Center - Baltimore
- St. Agnes Healthcare - Baltimore
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins - Baltimore
New Jersey
- Cooper Hospital/University Medical Center - Camden
- Monmouth Medical Center - Long Branch
- East Coast Radiation Oncology - Toms River
Arizona
- St. Joseph's Hospital and Medical Center - Phoenix
- Arizona Cancer Center - Tucson
Florida
- Comprehensive Cancer Care Specialists of Boca Raton - Boca Raton
- Citrus Memorial Hospital - Inverness
Massachusetts
- Lahey Clinic - Burlington - Burlington
- University of Massachusetts Memorial Medical Center - Worcester
Colorado
- University of Colorado Cancer Center - Denver
Illinois
- Decatur Memorial Hospital Cancer Care Institute - Decatur
Trial Details
| Field | Value |
|---|---|
| Start Date | 2000-02 |
| Est. Completion | 2003-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00005887
The ClinicalTrials.gov registry entry for NCT00005887 describes a study currently listed as completed, categorized as Phase 3. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Spectrum Pharmaceuticals, which has 52 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Metastatic Cancer appearing as the primary indexed condition, and to 2 interventions - of which radiation therapy is the first listed.
NCT00005887 reports 20 study locations spanning 10 distinct geographic areas - top geographies include California, Maryland, New Jersey.
Frequently Asked Questions
What is clinical trial NCT00005887 about?
NCT00005887 is a clinical study titled "Radiation Therapy With or Without RSR13 in Treating Patients With Brain Metastases". RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs such as RSR13 may make tumor cells more sensitive to radiation therapy. PURPOSE: Randomized phase III trial to compare the effectiveness of radiation therapy to the brain with or without RSR13 in treating patients who...
What is the current status of trial NCT00005887?
This trial is currently completed. It is a Phase 3 study. The study started on 2000-02. Estimated completion is 2003-01.
What conditions does trial NCT00005887 study?
This clinical trial studies the following conditions: Metastatic Cancer.
What interventions are being tested in trial NCT00005887?
The interventions under investigation include: radiation therapy (RADIATION), efaproxiral (DRUG).
Who is sponsoring clinical trial NCT00005887?
This trial is sponsored by Spectrum Pharmaceuticals, which has 52 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00005887 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Provide Continued Access to and Assess Long-Term Safety of the Study Drug(s)
RECRUITING · Phase 3
-
(Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors
ACTIVE NOT RECRUITING · Phase 3
-
Stereotactic Radiation Therapy With or Without Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases
COMPLETED · Phase 3
-
Zoledronate in Treating Patients With Solid Tumors That Have Spread to the Bone
COMPLETED · Phase 3
-
Talc in Treating Patients With Malignant Pleural Effusion
COMPLETED · Phase 3
-
Chemotherapy With or Without Isolated Hepatic Perfusion With Melphalan in Treating Patients With Colorectal Cancer That Has Spread to the Liver
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.